Women who took Orilissa for endometriosis or uterine fibroids may have a strong legal case against AbbVie, the drug’s maker. Lawsuits filed through 2025 and into 2026 allege the company knew about serious risks and failed to warn patients clearly enough.
The orilissa lawsuit centers on two main injuries: permanent bone density loss and severe mental health side effects including suicidal thoughts. These are not minor side effects listed in small print. They are life-changing conditions that patients say they were never properly warned about.
In this article, you’ll learn who qualifies, what the cases are worth, how to file, and what the latest court updates look like heading into 2026. You’ll also find out how long you have before your legal window closes.
Orilissa Lawsuit 2026: What’s Happening Right Now
Orilissa lawsuits are actively being filed in 2026, with litigation against AbbVie expanding as more women come forward with documented injuries. The cases are primarily individual personal injury claims, with attorneys across the country accepting clients who suffered bone loss, fractures, depression, or suicidal ideation while taking the drug.
As of 2026, there is no single nationwide class action settlement in place. Cases are being filed in state and federal courts, and legal pressure is mounting for a possible Multi-District Litigation (MDL) consolidation that would group similar cases before one federal judge.
The drug has been on the market since its FDA approval in July 2018. That’s nearly eight years of patients who may have suffered harm without realizing they had legal options.
| 2026 Lawsuit Status | Details |
|---|---|
| Litigation Type | Individual personal injury mass tort |
| Primary Defendant | AbbVie Inc. |
| Drug at Issue | Orilissa (elagolix) |
| FDA Approval Date | July 2018 |
| MDL Status | Consolidation discussions ongoing in 2026 |
| Main Injuries Claimed | Bone density loss, depression, suicidal thoughts |
The pace of filings has picked up since late 2024. Attorneys report a spike in inquiries from women who underwent DEXA scans and discovered significant bone loss they connect directly to Orilissa use.
What Is the Orilissa Lawsuit About?
The Orilissa lawsuit is a product liability and failure-to-warn case against AbbVie, alleging the company did not adequately disclose how dangerous the drug’s side effects could be. At its core, it’s a fight over informed consent: did patients truly know what they were agreeing to when they started taking this medication?
AbbVie marketed Orilissa as a treatment for moderate to severe endometriosis pain. It was later approved for heavy menstrual bleeding caused by uterine fibroids. Both uses involve suppressing estrogen production, which is where the danger begins.
Estrogen plays a big role in maintaining bone density. When Orilissa cuts off that hormone supply, bones can weaken fast. The lawsuits claim AbbVie knew this was happening at rates far more serious than the label suggested.
The three main legal theories plaintiffs are using:
- Failure to warn: AbbVie did not make the bone loss risk clear enough
- Design defect: The drug’s mechanism is inherently dangerous for long-term use
- Negligent marketing: AbbVie promoted the drug to patients who were not appropriate candidates
Think of it like a car manufacturer knowing its brakes fail in wet conditions but only mentioning it in the fine print of a 200-page manual. That’s the kind of failure to disclose these lawsuits are built on.
AbbVie Orilissa Lawsuit: The Company Behind the Drug
AbbVie Inc. is a global pharmaceutical giant headquartered in North Chicago, Illinois. The company is best known for Humira, once the best-selling drug in the world. AbbVie developed Orilissa in partnership with Neurocrine Biosciences.
The AbbVie orilissa lawsuit is not the company’s first major litigation rodeo. AbbVie has faced legal challenges over Depakote, AndroGel, and other blockbuster drugs. Critics say the company has a pattern of downplaying side effect severity to protect sales revenue.
Orilissa generated significant revenue since its 2018 launch. The financial stakes of litigation are high for AbbVie, which may influence how aggressively the company defends these cases.
| AbbVie Key Facts | Details |
|---|---|
| Headquarters | North Chicago, Illinois |
| Co-developer | Neurocrine Biosciences |
| Drug Brand Name | Orilissa |
| Generic Name | Elagolix |
| FDA Approval Year | 2018 |
| Primary Allegations | Failure to warn, product liability |
| Prior Drug Litigation | Depakote, AndroGel, Humira-related cases |
AbbVie has not publicly admitted wrongdoing related to Orilissa. The company has maintained that the drug’s label contains adequate warnings. Plaintiffs’ attorneys strongly disagree.
Key Takeaway: The Orilissa lawsuit is a product liability case against AbbVie alleging the company failed to properly warn patients about bone loss and serious mental health risks linked to the drug.
Who Qualifies for the Orilissa Lawsuit?
You may qualify for the Orilissa lawsuit if you took the drug and suffered serious physical or psychological harm as a result. Eligibility is not based on whether you experienced every side effect. Even one serious injury may be enough to support a claim.
Attorneys handling these cases are looking for clients who meet specific criteria. The more severe and documented the injury, the stronger the case.
Basic eligibility checklist:
- You were prescribed Orilissa (elagolix) at any point from 2018 to present
- You took the drug for endometriosis or uterine fibroid-related bleeding
- You experienced one or more of the following: significant bone density loss, fractures, depression, anxiety disorder, suicidal thoughts, or suicidal behavior
- You have medical records documenting the injury
- You filed or can still file within your state’s statute of limitations window
| Eligibility Factor | Requirement |
|---|---|
| Drug Used | Orilissa / elagolix |
| Conditions Treated | Endometriosis or uterine fibroids |
| Minimum Injury | Documented bone loss or mental health event |
| Medical Records | Required to support claim |
| Time Limit | Varies by state (typically 2 to 3 years from discovery) |
Patients who used Orilissa for just a few months can still qualify if they suffered measurable harm. Duration of use matters for severity, but it does not automatically disqualify short-term users.
Orilissa Bone Loss Lawsuit: The Core Injury Claim
Bone density loss is the central injury in the Orilissa lawsuit, and it’s the claim with the most scientific backing. Orilissa works by suppressing estrogen, and estrogen is essential for maintaining bone mineral density. Without it, bones weaken at a rate that can become permanent.
The FDA’s own label for Orilissa includes a warning about bone loss. The lawsuits argue that warning was buried, minimized, and inadequate. AbbVie also continued promoting long-term use despite knowing the risk increases with duration.
Women who took Orilissa for six months or longer are at the highest risk of measurable bone loss. Some patients have reported fractures, degenerative disc issues, and early-onset osteoporosis they attribute to the drug.
| Bone Loss Injury Type | Description |
|---|---|
| Bone Mineral Density (BMD) Reduction | Measurable loss shown on DEXA scan |
| Stress Fractures | Fractures with no major trauma event |
| Osteoporosis | Long-term thinning of bone structure |
| Vertebral Compression | Spine-related bone damage |
| Hip or Wrist Fractures | High-impact sites for density loss |
A DEXA scan is the standard test used to measure bone density. If you took Orilissa and haven’t had one, getting one now creates a medical record that supports your claim.
Orilissa Side Effects Lawsuit: What Injuries Are Covered?
The Orilissa side effects lawsuit covers a range of physical and psychological injuries, not just bone loss. Any serious harm that resulted from taking the drug and was inadequately disclosed can form the basis of a legal claim.
The FDA issued label updates over the years, but plaintiffs argue those updates came too late and were worded too vaguely to properly inform patients or their doctors of the real dangers.
Covered injuries in active 2026 claims include:
- Severe bone density loss or osteoporosis
- Bone fractures without major injury
- Clinical depression
- Anxiety disorders
- Suicidal ideation or suicidal behavior
- Attempted suicide
- Mood swings severe enough to require psychiatric treatment
- Hot flashes causing secondary health complications
- Cardiovascular stress from hormone suppression
The breadth of injuries covered is one reason these cases are gaining traction. It’s not a single side effect. It’s a pattern of serious harm across multiple body systems.
Key Takeaway: The Orilissa lawsuit covers both physical injuries like bone loss and fractures and psychological injuries like depression and suicidal ideation, giving many patients legitimate grounds to file a claim.
Orilissa Depression and Suicidal Thoughts Lawsuit
The link between Orilissa and serious psychiatric events is one of the most disturbing parts of this litigation. The FDA added a warning about suicidal ideation and behavior to the Orilissa label, but lawsuits allege this warning was not prominent enough and came too late for many patients.
Women have reported that they experienced severe depression, mood disorders, and suicidal thoughts that appeared shortly after starting Orilissa. Many had no prior history of mental illness.
This is not a case of the drug making existing conditions worse. Many plaintiffs describe it as a sudden, drug-induced psychological crisis that caught them and their families completely off guard.
| Mental Health Injury | Legal Significance |
|---|---|
| Clinical Depression (new onset) | Strong causation argument if no prior history |
| Suicidal Ideation | FDA acknowledged risk; warning timing challenged |
| Suicide Attempt | High-value individual claim |
| Anxiety Disorder (new onset) | Supported by pharmacological mechanism |
| Psychiatric Hospitalization | Documented damages strengthen claim value |
The FDA’s warning update on psychiatric side effects supports plaintiffs’ arguments that the risk was real and known. The question litigants are pressing: why did it take so long to update the label, and why wasn’t the warning stronger from the start?
Orilissa Long Term Side Effects: What Doctors Are Seeing
Long-term Orilissa side effects are emerging as an important part of the lawsuit narrative because some damage does not reverse after stopping the drug. That’s a key distinction from many pharmaceutical side effect cases.
Bone density loss from Orilissa may be partially irreversible. The FDA’s label acknowledges that bone loss “may not be fully reversible.” For patients who took the drug for extended periods, this means ongoing harm that continues years after their last dose.
Doctors are also seeing patients who stopped Orilissa but continue to experience hormonal disruption, mood instability, and joint pain. These ongoing conditions add to the damages calculation in personal injury claims.
Documented long-term effects reported in litigation:
- Persistent bone density reduction
- Irreversible vertebral changes
- Chronic depression continuing post-treatment
- Hormonal imbalance lasting months or years
- Increased fracture risk even after drug cessation
- Cardiovascular changes linked to estrogen suppression
The “long-tail” nature of these injuries matters legally. It means the harm didn’t stop when the prescription ended. That ongoing damage supports claims for future medical expenses and long-term pain and suffering damages.
Orilissa Lawsuit Settlement Amount: What to Expect
No global Orilissa settlement has been announced as of 2026, so there are no confirmed payout figures yet. However, attorneys handling these cases are providing estimates based on injury severity, which is how pharmaceutical mass torts typically calculate damages.
Settlement amounts in drug injury cases are based on a combination of factors. These include the severity of injury, whether the injury is permanent, the age of the plaintiff, documented medical costs, and the plaintiff’s pain and suffering.
Based on comparable pharmaceutical mass torts, here is a general estimate range attorneys are discussing:
| Injury Severity Tier | Estimated Settlement Range |
|---|---|
| Tier 1: Mild bone loss, no fracture | $25,000 to $75,000 |
| Tier 2: Moderate bone loss or documented depression | $75,000 to $200,000 |
| Tier 3: Severe bone loss, fractures, or psychiatric hospitalization | $200,000 to $500,000 |
| Tier 4: Suicide attempt or permanent disability | $500,000 to $1,000,000+ |
These are estimates, not guarantees. Actual payouts depend on individual case facts, how courts value the claims, and whether AbbVie chooses to settle or fight each case.
Key Takeaway: Orilissa lawsuit settlement amounts are estimated between $25,000 and over $1 million depending on injury severity, with no global settlement announced yet as of 2026.
Is There an Orilissa Class Action Lawsuit?
The Orilissa litigation is not a traditional class action lawsuit. It is being pursued as a mass tort, which is an important distinction for anyone who wants to understand their potential payout.
In a class action, all plaintiffs share one settlement pot and receive small, often identical payments. In a mass tort, each plaintiff files their own individual claim. That means each person’s case is evaluated on its own facts, and payouts are based on individual injury severity.
The mass tort structure generally produces much larger individual recoveries than class actions for serious injuries. A woman with permanent bone damage and documented psychiatric treatment will not get the same recovery as someone with minimal documented harm.
| Class Action vs. Mass Tort | Details |
|---|---|
| Class Action | One shared settlement, equal or formulaic payouts |
| Mass Tort | Individual claims, injury-based payouts |
| Orilissa Structure | Mass tort (individual claims) |
| MDL Possibility | Federal consolidation for pretrial efficiency |
| Individual Recovery Potential | Higher than class action for serious injuries |
An MDL (Multi-District Litigation) may form in 2026. This groups cases before one judge for pretrial proceedings but preserves each plaintiff’s individual claim. It’s the most common structure for large-scale pharmaceutical litigation.
Orilissa Elagolix Lawsuit: The Drug’s Chemical Identity
Elagolix is the generic chemical name for Orilissa, and understanding this matters if you’re searching for your lawsuit options. Some legal filings, FDA documents, and medical records use “elagolix” rather than “Orilissa.” They refer to the same drug.
AbbVie also markets elagolix under the brand name Oriahnn, which is used specifically for uterine fibroids (combined with hormonal add-back therapy). If you took Oriahnn, you may also have grounds for a related claim.
The elagolix mechanism is a GnRH (gonadotropin-releasing hormone) antagonist. It essentially shuts down the body’s production of estrogen and progesterone. That hormone suppression is why it works for endometriosis, and why it causes such serious side effects.
| Drug Name | Details |
|---|---|
| Brand Name (endometriosis) | Orilissa |
| Brand Name (uterine fibroids) | Oriahnn |
| Generic/Chemical Name | Elagolix |
| Drug Class | GnRH antagonist |
| Manufacturer | AbbVie Inc. |
| Co-developer | Neurocrine Biosciences |
| FDA Approval (Orilissa) | July 2018 |
| FDA Approval (Oriahnn) | May 2020 |
If your prescription bottle says “elagolix” or “Oriahnn,” your claim still falls under this same body of litigation. The chemical is the same. The manufacturer is the same. The alleged failures are the same.
Orilissa Lawsuit Update 2026: Where Cases Stand Today
As of 2026, the Orilissa lawsuit landscape is in an active and evolving phase. Attorneys across the country are accepting new clients, case filings are increasing, and legal experts expect formal litigation structures to become clearer by mid-2026.
There has been no trial verdict and no global settlement as of early 2026. This is consistent with how large pharmaceutical mass torts typically develop. They take several years to mature from initial filings to resolution.
Key developments heading into 2026 include growing attorney advertising campaigns targeting Orilissa users, increasing medical research linking elagolix to serious bone and psychiatric outcomes, and mounting pressure on AbbVie from multiple simultaneous lawsuits.
2026 litigation timeline snapshot:
- 2018: FDA approves Orilissa; initial safety concerns noted
- 2019 to 2020: FDA label updates on bone loss and psychiatric risks
- 2021 to 2023: First individual lawsuits begin emerging
- 2024: Attorney activity increases significantly
- 2025: Case filings accelerate; MDL discussions begin
- 2026: Active litigation phase; no settlement yet; deadlines tightening
The absence of a settlement is not a sign the cases are weak. It means they are still in the litigation phase. AbbVie has strong financial incentives to delay resolution as long as possible.
Key Takeaway: The Orilissa lawsuit update for 2026 shows active and growing litigation with no global settlement yet, making this a critical year for new plaintiffs to file before deadlines expire.
How Much Can You Get From the Orilissa Lawsuit?
What you can recover from an Orilissa lawsuit depends heavily on the type and severity of your injury and how well it’s documented. Pharmaceutical personal injury cases award damages across several categories.
Courts and settlement agreements in drug injury cases typically award three types of damages. These are economic damages (actual financial losses), non-economic damages (pain and suffering), and sometimes punitive damages (designed to punish the wrongdoer).
Here’s a breakdown of what goes into your total recovery:
| Damage Category | What It Covers |
|---|---|
| Medical Expenses (past) | Hospital bills, DEXA scans, psychiatric treatment |
| Medical Expenses (future) | Ongoing treatment for permanent bone damage |
| Lost Wages | Income lost due to injury or treatment |
| Pain and Suffering | Physical pain from fractures or bone loss |
| Emotional Distress | Depression, anxiety, trauma from side effects |
| Loss of Quality of Life | Inability to perform normal activities |
| Punitive Damages | If AbbVie’s conduct is found reckless or intentional |
Plaintiffs with documented fractures, hospitalizations, or suicide attempts tend to receive the highest awards. Well-organized medical records are the single biggest factor in maximizing your recovery.
How to File an Orilissa Lawsuit
Filing an Orilissa lawsuit starts with finding a qualified mass tort attorney who handles pharmaceutical injury cases. You do not pay upfront fees. These cases are handled on contingency, meaning the attorney only gets paid if you win or settle.
The process is more straightforward than many people expect. Think of it like reporting a car accident to your insurance: you gather your evidence, work with your attorney to file the claim, and then let the legal process move forward.
Step-by-step filing process:
- Gather your medical records confirming Orilissa use and documented injuries
- Get a DEXA scan if you haven’t had one (bone density test)
- Collect pharmacy records proving you were prescribed elagolix
- Contact a mass tort attorney for a free case evaluation
- Sign a contingency fee agreement (no upfront cost)
- Attorney files your complaint in the appropriate court
- Case enters discovery and litigation or settlement process
| Filing Requirement | What You Need |
|---|---|
| Proof of Orilissa Use | Prescription records or pharmacy history |
| Proof of Injury | Medical records, DEXA scan, psychiatric notes |
| Attorney Representation | Mass tort or pharmaceutical injury attorney |
| Filing Fee | None (contingency basis) |
| Time to File | Varies by state; act before deadline |
Do not wait to gather records. The older the case, the harder it becomes to obtain complete documentation.
Orilissa Lawsuit Statute of Limitations
The statute of limitations for the Orilissa lawsuit varies by state, but most states give plaintiffs two to three years from the date they discovered the injury. “Discovery” doesn’t always mean when you started taking the drug. It often means when you first connected your injury to Orilissa.
This discovery rule is important for Orilissa cases because many women didn’t know bone loss or depression could be caused by their medication. The clock may have started when your doctor first told you about bone density loss on a DEXA scan.
| State Statute of Limitations | Time Limit |
|---|---|
| California | 2 years from discovery |
| Texas | 2 years from discovery |
| New York | 3 years from discovery |
| Florida | 2 years from discovery |
| Illinois | 2 years from discovery |
| Pennsylvania | 2 years from discovery |
| Most other states | 2 to 3 years from discovery |
These deadlines are hard cutoffs. Missing your state’s statute of limitations means losing your right to sue permanently, regardless of how strong your case is.
An attorney can tell you exactly where you stand based on your specific timeline. Getting a free evaluation costs nothing and clarifies your deadline immediately.
Orilissa Lawsuit Filing Deadline 2026: Don’t Miss This Window
The Orilissa lawsuit filing deadline in 2026 is one of the most urgent issues for potential plaintiffs, because women who took Orilissa between 2018 and 2022 may be running out of time. If you took the drug in the early years after its approval, your window could close in 2026 or early 2027.
This is not a warning to cause panic. It’s a practical reality of how statutes of limitations work. The legal system does not make exceptions for people who didn’t know they had options.
Key 2026 deadline considerations:
- Women who took Orilissa in 2018 to 2019 and discovered harm in 2023 to 2024 may be at or near their two-year deadline in 2025 to 2026
- Women who discovered harm more recently have more time but should still act promptly
- MDL consolidation does not stop individual statutes of limitations from running
- Filing a claim preserves your rights even while litigation is ongoing
| Timeline Example | Deadline Implication |
|---|---|
| Took Orilissa 2018, discovered harm 2022 | Deadline may be 2024 (already expired) |
| Took Orilissa 2020, discovered harm 2023 | Deadline may be 2025 (urgent) |
| Took Orilissa 2021, discovered harm 2024 | Deadline may be 2026 (act now) |
| Took Orilissa 2022 to 2023, discovered harm recently | More time, but don’t delay |
If there’s any chance you qualify, the safest move is to get a free case evaluation in 2026. You don’t have to commit to anything. You just need to know where you stand before the clock runs out.
Frequently Asked Questions
What is the Orilissa lawsuit about?
The Orilissa lawsuit is a product liability case against AbbVie alleging the company failed to adequately warn patients about serious risks including bone density loss and suicidal thoughts.
Women who took Orilissa for endometriosis or uterine fibroids and suffered these injuries are suing for compensation.
The core legal theory is failure to warn: that AbbVie knew about these risks but did not make them clear enough to patients or doctors.
Who qualifies for the Orilissa lawsuit in 2026?
You may qualify if you were prescribed Orilissa (elagolix), took it for endometriosis or uterine fibroids, and suffered documented bone loss, fractures, depression, or suicidal thoughts.
Medical records proving both your drug use and your injury are required to support a claim.
Even short-term users may qualify if they suffered serious documented harm during or after their treatment period.
How much money can I get from an Orilissa lawsuit?
Individual Orilissa lawsuit payouts are estimated between $25,000 and over $1 million depending on injury severity.
Serious injuries like fractures, psychiatric hospitalization, or suicide attempts typically support the highest damage awards.
No global settlement has been announced yet, so these are projections based on comparable pharmaceutical mass tort outcomes.
Has AbbVie settled the Orilissa lawsuit?
AbbVie has not announced any global settlement for Orilissa lawsuits as of 2026.
Cases are in active litigation, with individual claims being filed and case law developing.
Settlement negotiations may intensify in 2026 and beyond as the volume of claims continues to grow.
What is the deadline to file an Orilissa lawsuit?
The deadline to file an Orilissa lawsuit depends on your state’s statute of limitations, which is typically two to three years from when you discovered your injury.
Women who took Orilissa in the early years after its 2018 approval and discovered harm between 2022 and 2024 may be facing deadlines in 2026.
Getting a free case evaluation now is the fastest way to find out your exact deadline before you lose your right to file.
The Orilissa litigation is at a pivotal point in 2026. AbbVie has not settled, cases are mounting, and the evidence against the drug’s safety record is getting stronger with every new study and DEXA scan result.
If you took Orilissa and experienced bone loss, fractures, depression, or suicidal thoughts, your window to file a claim may be closing. Gather your medical and pharmacy records now.
Get a free case evaluation from a mass tort attorney. It costs nothing and tells you immediately whether you have a claim worth pursuing.
